Oppenheimer raised the firm’s price target on Regeneron (REGN) to $865 from $750 and keeps an Outperform rating on the shares. The firm notes Regeneron reported Q4 earnings that were largely in line with its/consensus estimates. After four straight quarters where EYLEA’s troubles dominated the discussion, Oppenheimer thought the Q4 call sounded refreshingly optimistic, with an emphasis on future opportunities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces upcoming presentations at Angiogenesis annual meeting
- Regeneron price target raised to $950 from $850 at JPMorgan
- Regeneron price target raised to $800 from $745 at Wells Fargo
- Regeneron price target raised to $769 from $768 at Morgan Stanley
- Balanced Risk/Reward Keeps Regeneron at Hold Amid Solid Fundamentals and Pipeline Uncertainty